GLP-1 clinical studies

Published trials by medicine, population and endpoint, with results and original sources.

Clinical trial results at a glance

All weight charts

Phase 3b · 72 weeks

STEP UP

Wegovy injection

Mean body weight change

Semaglutide 7.2 mg: −18.7%
Semaglutide 2.4 mg: −15.6%
Placebo: −3.9%

Phase 3b · 72 weeks

SURMOUNT-5

MounjaroWegovy injection

Mean body weight change

Tirzepatide 10 or 15 mg: −20.2%
Semaglutide 1.7 or 2.4 mg: −13.7%

Phase 3b · 64 weeks

OASIS 4

Wegovy tablets

Mean body weight change

Oral semaglutide 25 mg: −13.6%
Placebo: −2.2%

Study register

19 of 19 studies

Search trialsMedicineOutcome

Study	Medicine	Population & follow-up	Published results	Source
ATTAIN-JPhase 3 · 2026 · 238 participants FoundayoJapan · mixed diabetes status · 72 weeks	Foundayo	Japan · mixed diabetes status72 weeks	Mean body weight change at 72 weeks Orforglipron 6 mg −5.9% Orforglipron 12 mg −8.7% Orforglipron 36 mg −7.9% Placebo −0.6%	Paper
ATTAIN-MAINTAINPhase 3b · 2026 · 376 participants FoundayoAfter injectable treatment · 52 weeks	Foundayo	After injectable treatment52 weeks	Estimated share of earlier weight loss maintained at week 52 among participants who had reached a weight plateau Orforglipron after tirzepatide 74.7% Placebo after tirzepatide 49.2% Orforglipron after semaglutide 79.3% Placebo after semaglutide 37.6%	Paper
SYNCHRONIZE-1Phase 3 · 2026 · 726 participants SurvodutideWithout diabetes · 76 weeks	Survodutide	Without diabetes76 weeks	Mean body weight change at 76 weeks Survodutide up to 3.6 mg −12.2% Survodutide up to 6.0 mg −13.0% Placebo −5.4%	Paper
TRIUMPH-1Phase 3 · 2026 · 2,339 participants RetatrutideWithout diabetes · 80 weeks	Retatrutide	Without diabetes80 weeks	Mean body weight change at 80 weeks Retatrutide 4 mg −17.6% Retatrutide 9 mg −23.7% Retatrutide 12 mg −25.0% Placebo −3.9%	Paper
OASIS 4Phase 3b · 2025 · 307 participants Wegovy tabletsWithout diabetes · 64 weeks	Wegovy tablets	Without diabetes64 weeks	Mean body weight change at 64 weeks Oral semaglutide 25 mg −13.6% Placebo −2.2%	Paper
ATTAIN-1Phase 3 · 2025 · 3,127 participants FoundayoWithout diabetes · 72 weeks	Foundayo	Without diabetes72 weeks	Mean body weight change at 72 weeks Orforglipron 6 mg −7.5% Orforglipron 12 mg −8.4% Orforglipron 36 mg −11.2% Placebo −2.1%	Paper
SURMOUNT-5Phase 3b · 2025 · 751 participants MounjaroWegovy injectionWithout type 2 diabetes · 72 weeks	MounjaroWegovy injection	Without type 2 diabetes72 weeks	Mean body weight change at 72 weeks Tirzepatide 10 or 15 mg −20.2% Semaglutide 1.7 or 2.4 mg −13.7%	Paper
ATTAIN-2Phase 3 · 2025 · 1,613 participants FoundayoWith type 2 diabetes · 72 weeks	Foundayo	With type 2 diabetes72 weeks	Mean body weight change at 72 weeks Orforglipron 6 mg −5.1% Orforglipron 12 mg −7.0% Orforglipron 36 mg −9.6% Placebo −2.5%	Paper
STEP UPPhase 3b · 2025 · 1,407 participants Wegovy injectionWithout diabetes · 72 weeks	Wegovy injection	Without diabetes72 weeks	Mean body weight change at 72 weeks Semaglutide 7.2 mg −18.7% Semaglutide 2.4 mg −15.6% Placebo −3.9%	Paper
REDEFINE 1Phase 3a · 2025 · 3,417 participants CagriSemaWegovy injectionWithout diabetes · 68 weeks	CagriSemaWegovy injection	Without diabetes68 weeks	Mean body weight change at 68 weeks CagriSema 2.4 mg / 2.4 mg −20.4% Semaglutide 2.4 mg −14.9% Cagrilintide 2.4 mg −11.5% Placebo −3.0%	Paper
GLORY-1Phase 3 · 2025 · 610 participants MazdutideChina · without diabetes · 32 weeks	Mazdutide	China · without diabetes32 weeks	Mean body weight change at 32 weeks Mazdutide 4 mg −10.09% Mazdutide 6 mg −12.55% Placebo +0.45%	Paper
SELECTPhase 3 · 2023 · 17,604 participants Wegovy injectionEstablished cardiovascular disease · 39.8 months	Wegovy injection	Established cardiovascular disease39.8 months	Participants with a major cardiovascular event over 39.8 months of mean follow-up Semaglutide 2.4 mg 6.5% Placebo 8.0%	Paper
SURMOUNT-2Phase 3 · 2023 · 938 participants MounjaroWith type 2 diabetes · 72 weeks	Mounjaro	With type 2 diabetes72 weeks	Mean body weight change at 72 weeks Tirzepatide 10 mg −12.8% Tirzepatide 15 mg −14.7% Placebo −3.2%	Paper
SURMOUNT-4Phase 3 · 2023 · 670 participants MounjaroAfter tirzepatide lead-in · 52 weeks	Mounjaro	After tirzepatide lead-in52 weeks	Mean body weight change from week 36 to week 88 Continued tirzepatide 10 or 15 mg −5.5% Switched to placebo +14.0%	Paper
Retatrutide phase 2Phase 2 · 2023 · 338 participants RetatrutideWithout diabetes · 24 weeks	Retatrutide	Without diabetes24 weeks	Mean body weight change at 24 weeks Retatrutide 1 mg −7.2% Retatrutide 4 mg (pooled) −12.9% Retatrutide 8 mg (pooled) −17.3% Retatrutide 12 mg −17.5% Placebo −1.6%	Paper
SURMOUNT-1Phase 3 · 2022 · 2,539 participants MounjaroWithout diabetes · 72 weeks	Mounjaro	Without diabetes72 weeks	Mean body weight change at 72 weeks Tirzepatide 5 mg −15.0% Tirzepatide 10 mg −19.5% Tirzepatide 15 mg −20.9% Placebo −3.1%	Paper
STEP 5Phase 3 · 2022 · 304 participants Wegovy injectionWithout diabetes · 104 weeks	Wegovy injection	Without diabetes104 weeks	Mean body weight change at 104 weeks Semaglutide 2.4 mg −15.2% Placebo −2.6%	Paper
STEP 1Phase 3 · 2021 · 1,961 participants Wegovy injectionWithout diabetes · 68 weeks	Wegovy injection	Without diabetes68 weeks	Mean body weight change at 68 weeks Semaglutide 2.4 mg −14.9% Placebo −2.4%	Paper
STEP 4Phase 3 · 2021 · 803 participants Wegovy injectionAfter semaglutide lead-in · 48 weeks	Wegovy injection	After semaglutide lead-in48 weeks	Mean body weight change from week 20 to week 68 Continued semaglutide 2.4 mg −7.9% Switched to placebo +6.9%	Paper

Open a study to see doses, comparators and the exact endpoint.